Intellia Therapeutics Reports Q3 Loss of $127.5 Million and EPS of -$0.91, Missing Analyst Estimates
Pipeline Progress and Cash Runway Extend into 2028 Ahead of Key Regulatory Milestone Related Stocks: NTLA ,
Pipeline Progress and Cash Runway Extend into 2028 Ahead of Key Regulatory Milestone Related Stocks: NTLA ,